Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma

被引：4

作者：

Usta, Sena Zeynep ^{[1
]}

Uchihashi, Toshihiro ^{[1
]}

Kodama, Shingo ^{[1
]}

Kurioka, Kyoko ^{[1
]}

Inubushi, Toshihiro ^{[2
]}

Shimooka, Takuya ^{[1
]}

Sugauchi, Akinari ^{[1
,3
]}

Seki, Soju ^{[1
]}

Tanaka, Susumu ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg, 1-8 Yamadaoka, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, Osaka 5650871, Japan

[3] Osaka Univ Hosp, Unit Dent, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 24期

基金：

日本学术振兴会;

关键词：

immune checkpoint inhibitor; resistance mechanism; melanoma; oral mucosal melanoma; immunotherapy; immune checkpoint blockade; anti-PD-1; anti-CTLA-4; REGULATORY T-CELLS; NECK MUCOSAL MELANOMA; STAGE-III MELANOMA; METASTATIC MELANOMA; INDOLEAMINE 2,3-DIOXYGENASE; PD-1/PD-L1; BLOCKADE; CANCER-TREATMENT; CTLA-4; DOWN-REGULATION; IPILIMUMAB;

D O I：

10.3390/ijms242417282

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) antibodies, have initiated a new era in the treatment of malignant melanoma. ICIs can be used in various settings, including first-line, adjuvant, and neo-adjuvant therapy. In the scope of this review, we examined clinical studies utilizing ICIs in the context of treating oral mucosal melanoma, a rare disease, albeit with an extremely poor prognosis, with a specific focus on unraveling the intricate web of resistance mechanisms. The absence of a comprehensive review focusing on ICIs in oral mucosal melanoma is notable. Therefore, this review seeks to address this deficiency by offering a novel and thorough analysis of the current status, potential resistance mechanisms, and future prospects of applying ICIs specifically to oral malignant melanoma. Clarifying and thoroughly understanding these mechanisms will facilitate the advancement of effective therapeutic approaches and enhance the prospects for patients suffering from oral mucosal melanoma.

引用

页数：27

共 129 条

[61] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma [J].

Mahoney, Kathleen M. ;

Freeman, Gordon J. ;

McDermott, David F. .

CLINICAL THERAPEUTICS, 2015, 37 (04) :764-782

[62]

Maitituoheti M., 2022, bioRxiv, DOI [10.1101/2022.08.31.506051, DOI 10.1101/2022.08.31.506051]

[63] Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor [J].

Maj, Tomasz ;

Wang, Wei ;

Crespo, Joel ;

Zhang, Hongjuan ;

Wang, Weimin ;

Wei, Shuang ;

Zhao, Lili ;

Vatan, Linda ;

Shao, Irene ;

Szeliga, Wojciech ;

Lyssiotis, Costas ;

Liu, J. Rebecca ;

Kryczek, Ilona ;

Zou, Weiping .

NATURE IMMUNOLOGY, 2017, 18 (12) :1332-+

[64] DYNAMIC IMMUNE LANDSCAPES DURING MELANOMA PROGRESSION REVEAL A ROLE FOR ENDOGENOUS OPIOIDS IN DRIVING T CELL DYSFUNCTION [J].

Mangani, Davide ;

Huang, Linglin ;

Singer, Meromit ;

Li, Ruitong ;

Barilla, Rocky ;

Escobar, Giulia ;

Tooley, Katherine ;

Cheng, Hanning ;

Delaney, Conor ;

Newcomer, Kathleen ;

Nyman, Jackson ;

Marjanovic, Nemanja ;

Nevin, James ;

Rozenblatt-Rosen, Orit ;

Kuchroo, Vijay ;

Regev, Aviv ;

Anderson, Ana .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 :A1005-A1005

[65] TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells [J].

Mariathasan, Sanjeev ;

Turley, Shannon J. ;

Nickles, Dorothee ;

Castiglioni, Alessandra ;

Yuen, Kobe ;

Wang, Yulei ;

Kadel, Edward E., III ;

Koeppen, Hartmut ;

Astarita, Jillian L. ;

Cubas, Rafael ;

Jhunjhunwala, Suchit ;

Banchereau, Romain ;

Yang, Yagai ;

Guan, Yinghui ;

Chalouni, Cecile ;

Ziai, James ;

Senbabaoglu, Yasin ;

Santoro, Stephen ;

Sheinson, Daniel ;

Hung, Jeffrey ;

Giltnane, Jennifer M. ;

Pierce, Andrew A. ;

Mesh, Kathryn ;

Lianoglou, Steve ;

Riegler, Johannes ;

Carano, Richard A. D. ;

Eriksson, Pontus ;

Hoglund, Mattias ;

Somarriba, Loan ;

Halligan, Daniel L. ;

van der Heijden, Michiel S. ;

Loriot, Yohann ;

Rosenberg, Jonathan E. ;

Fong, Lawrence ;

Mellman, Ira ;

Chen, Daniel S. ;

Green, Marjorie ;

Derleth, Christina ;

Fine, Gregg D. ;

Hegde, Priti S. ;

Bourgon, Richard ;

Powles, Thomas .

NATURE, 2018, 554 (7693) :544-+

[66] MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2 [J].

Markovits, Ettai ;

Harush, Ortal ;

Baruch, Erez N. ;

Shulman, Eldad D. ;

Debby, Assaf ;

Itzhaki, Orit ;

Anafi, Liat ;

Danilevsky, Artem ;

Shomron, Noam ;

Ben-Betzalel, Guy ;

Asher, Nethanel ;

Shapira-Frommer, Ronnie ;

Schachter, Jacob ;

Barshack, Iris ;

Geiger, Tamar ;

Elkon, Ran ;

Besser, Michal J. ;

Markel, Gal .

CANCER IMMUNOLOGY RESEARCH, 2023, 11 (07) :909-924

[67] Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance [J].

Mascitti, Marco ;

Santarelli, Andrea ;

Sartini, Davide ;

Rubini, Corrado ;

Colella, Giuseppe ;

Salvolini, Eleonora ;

Ganzetti, Giulia ;

Offidani, Annamaria ;

Emanuelli, Monica .

MELANOMA RESEARCH, 2019, 29 (02) :151-156

[68] Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab [J].

Meyer, Christiane ;

Cagnon, Laurene ;

Costa-Nunes, Carla M. ;

Baumgaertner, Petra ;

Montandon, Nicole ;

Leyvraz, Loredana ;

Michielin, Olivier ;

Romano, Emanuela ;

Speiser, Daniel E. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (03) :247-257

[69] Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037) [J].

Mitchell, Tara C. ;

Hamid, Omid ;

Smith, David C. ;

Bauer, Todd M. ;

Wasser, Jeffrey S. ;

Olszanski, Anthony J. ;

Luke, Jason J. ;

Balmanoukian, Ani S. ;

Schmidt, Emmett V. ;

Zhao, Yufan ;

Gong, Xiaohua ;

Maleski, Janet ;

Leopold, Lance ;

Gajewski, Thomas F. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) :3223-+

[70] eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma [J].

Moya-Plana, Antoine ;

Ngo, Carine ;

Lanoy, Emilie ;

Vagner, Stephan ;

Robert, Caroline .

EUROPEAN JOURNAL OF CANCER, 2023, 184 :120-123

← 2 3 4 5 6 7 8 9 10 11 →